**QUEEN'S
UNIVERSITY
BELFAST**

Potential strategies for the eradication of multi-drug resistant Gram-negative bacterial infections

Huwaitat, R., McCloskey, A. P., Gilmore, B. F., & Lavery, G. (2016). Potential strategies for the eradication of multi-drug resistant Gram-negative bacterial infections. *Future microbiology*, 11(7), 955-972.
<https://doi.org/10.2217/fmb-2016-0035>

Published in:
Future microbiology

Document Version:
Early version, also known as pre-print

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights
© 2016 The Authors.
Article has been submitted for publication to Future Microbiology.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Potential strategies for the selective eradication of multi-drug resistant Gram-negative
bacterial infections

Rawan Huwaitat, Alice P. McCloskey, Brendan F. Gilmore, Garry Lavery*

*Biofunctional Nanomaterials Group, School of Pharmacy, Queens University of Belfast,
Medical Biology Centre, 97 Lisburn Road, Belfast, BT9 7BL, UK*

*Author for Correspondence

Dr Garry Lavery,
School of Pharmacy
Queen's University of Belfast,
Medical Biology Centre,
97 Lisburn Road,
Belfast, BT9 7BL, UK

Tel: +44 (0) 28 9097 2273

Fax: +44 (0) 28 90 247 794

Email: garry.lavery@qub.ac.uk

Keywords

Antibiotic resistance, efflux pumps, lipopolysaccharide, nosocomial, nanomaterial, outer membrane, polymyxin.

Abstract

Antimicrobial resistance is one of the leading threats to society. The increasing burden of multidrug-resistant Gram-negative infection is particularly concerning as such bacteria are demonstrating resistance to nearly all currently licensed therapies. Various strategies have been hypothesised to treat multidrug-resistant Gram-negative infections including: targeting the Gram-negative outer membrane; neutralization of lipopolysaccharide; inhibition of bacterial efflux pumps and prevention of protein folding. Silver and silver nanoparticles, fusogenic liposomes and nanotubes are potential strategies for extending the activity of licensed, Gram-positive selective, antibiotics to Gram-negatives. This may serve as a strategy to fill the current void in pharmaceutical development in the short-term. This review outlines the most promising strategies that could be implemented to solve the threat of multidrug-resistant Gram-negative infections.

Introduction

There is a drastic need for innovative therapeutic solutions that selectively target multi-drug resistant Gram-negative infections. This can be attributed to resistance to nearly all conventional antibiotics used clinically, and a lack of effective antibiotics in reserve. Gram-negative bacteria, particularly: *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae* and *Acinetobacter baumannii*, are an ever-increasing threat to health and

particularly that of hospitalized patients who commonly are immunocompromised, have co-morbidities and are less able to fight infection [1]. Recently, emphasis has been placed on the rapid detection of specific, causative antimicrobial resistant strains. This has catalysed the drive to develop pathogen-specific, narrow spectrum antimicrobials. This change in focus from broad-spectrum microbial annihilation to more targeted therapy, acknowledges the major contribution empirical prescribing has on increasing drug resistance, and its impact on beneficial human microbiota [2].

Nosocomial infections are a major contributor to healthcare associated infections and antimicrobial resistance. Approximately 20-40% are attributed to transfer of commensal microorganisms from the skin of healthcare workers to patients or even the patients' own commensal flora [3]. Healthcare associated infections affect approximately 4.1 million patients annually within the European Union. They are a major contributor to morbidity causing 37, 000 deaths annually and a further 100,000 deaths in those with co-morbidities [4]. In terms of antimicrobial resistant infections, recent UK government reports estimate that these contribute to around 25,000 deaths annually in Europe alone [5].

Gram-negative bacteria are a particular problem due to multiple inherent resistance mechanisms, most notably the presence of a lipopolysaccharide (LPS) outer membrane and efflux pumps [6]. As a result of improper and overuse of antimicrobials, the resistance rates to current therapeutic agents have increased to serious levels. This dilemma has attracted the attention of scientists, the general public, health authorities and politicians. It is now recognized as a considerable global health problem [3]. As mentioned, the significant lack of newly licensed antimicrobial pharmaceuticals translating from the laboratory to patients is

concerning. In the past 25 years, only two new cephalosporin-beta-lactamase inhibitor combinations- ceftolozane/tazobactam in 2014 and ceftazidime/avibactam in 2015 have been approved to treat systemic bacterial infections caused by multi-drug resistant Gram-negative bacteria [7]. There are a multitude of reasons for the decline in antimicrobial drug development, most notably the high financial commitment and time required for developing and registering a new drug. On average it costs approximately \$800 million to introduce a new drug to market with development times normally in excess of 10 years. Parallel to this, the pharmaceutical industry has focused over the past 30 years on the more financially rewarding novel therapies for chronic diseases such as diabetes and cardiovascular disorders. These products are likely to be required as lifetime treatments in contrast to antibiotics that are most commonly short-term acute treatments (typically 5- 14 days) [8]. Other contributing factors include clinical trial requirements, particularly the challenge of proving novel therapies produce greater clinical outcomes compared to existing products, and that they are sufficiently safe for use. Pharmaceutical companies also express reservations about future resistance development that may reduce drug longevity [9][10]. In order to increase the approval and registration of new antimicrobials, the US Food and Drug Administration have indicated that it may be ready to alter its strict clinical-trial requirements and reassess the antimicrobial approval regulations in order to increase the potential availability of novel treatments [11]. The primary barriers to overcome, as will be discussed further in this review, include the specific targeting of Gram-negative bacteria in order to produce selective antibiotics that are suitable candidates for clinical trials and transition from the lab bench to the clinic.

The Gram-negative outer membrane as a barrier to therapy

I. Bacterial cell wall structure

Understanding the mechanisms that govern Gram-negative bacterial resistance requires a fundamental appreciation of their cell morphology. The unique structure of the outer membrane of Gram-negative bacteria plays an important role, providing an additional layer of mechanical protection, without affecting the selectivity or exchange of material needed for bacterial survival [12]. The Gram-negative cell wall is composed of an outer LPS membrane and an inner cytoplasmic membrane. A thin layer of peptidoglycan and lipoproteins exist within the periplasmic space. The inner cell membrane is composed of a phospholipid bilayer, whilst the outer membrane consists of phospholipids on its interior leaflet and of LPS on its outer leaflet [13]. Porins and specialized transporters are also present within the outer membrane channels and mediate the influx of a variety of compounds including nutrients and minerals such as sugars, amino acids, phosphates and ions. Porins play an important role in bacterial metabolism and growth, and are therefore a valuable target for antimicrobial drug development [14]. Gram-negative bacteria continuously alter the expression and function of outer membrane porins hence this may affect the sensitivity of antimicrobial agents. Loss of or changes in porin amino acids could influence the ability or rate of entry of antibiotics and contribute to resistance. In contrast to Gram-negative bacteria, Gram-positive bacteria lack an outer membrane and are composed of a single lipid membrane surrounded by numerous interconnecting layers of peptidoglycan and lipoteichoic acid (Figure 1) [15]. Although Gram-positive bacteria possess a cell membrane, the lack of a protective outer membrane makes them more susceptible to antibiotics.

II. Antimicrobial resistance mechanisms of Gram-negative bacterial cell wall

116 The outer membrane of Gram-negative bacteria acts as a selective barrier by adding a
117 hydrophobic lipid bilayer to the specific size-exclusion properties of porins. The outer
118 membrane has the ability to block the entry of numerous toxic compounds and prevent the
119 uptake of molecules with a molecular mass greater than 600 Daltons [16]. The influx of
120 metabolites such as sugars, phosphates and hydrophilic molecules is mainly directed by
121 porins. The continuous alteration in lipid or protein composition of the outer membrane leads
122 to drug-resistance. This involves the increasing of outer membrane hydrophobicity, changing
123 porin specificity or increasing the number and efficacy of efflux pumps [17].

124

125 Reducing the negative charge of LPS within the bacterial outer membrane is one of the key
126 strategies employed by Gram-negative bacteria to negate the action of membrane active
127 cationic antimicrobials, such as chlorhexidine and cationic antimicrobial peptides. This is
128 achieved via the addition of positively charged residues such as aminoarabinose and
129 galactosamine sugars to LPS or by the removal of negative charged moieties. This
130 modification leads to increased bacterial survival as demonstrated by both *Pseudomonas*
131 *aeruginosa* and *Francisella novicida* after exposure to the cyclic cationic lipopeptide
132 polymyxin B [18]. Amines are also harnessed by Gram-negatives to increase LPS membrane
133 cationicity as demonstrated by *Salmonella typhimurium* which increases tolerance to
134 polymyxin B by conjugating phosphoethanolamine to one of the phosphate groups present
135 within outer membrane lipid A [19]. Bacteria are also able to remove anionic phosphate
136 groups to reduce the overall anionic surface charge of LPS, proven by the removal of the 4'-
137 phosphate group from lipid A in *Helicobacter pylori*. This results in increased resistance to
138 membrane active cationic antimicrobial peptides [20]. Phospholipids present in the Gram-
139 negative outer membrane are also susceptible to modification. *Salmonella typhimurium* has
140 the ability to increase the levels of outer membrane glycerophospholipids resulting in

increased membrane hydrophobicity and reducing the permeability of charged, water soluble molecules [21].

Alteration of outer membrane porins prevent intracellular diffusion of small hydrophilic antibiotics such as beta-lactams, tetracycline, chloramphenicol and fluoroquinolones. Research has revealed that functional changes in porins are directed by specific mutations in a variety of pathogens, including *Escherichia coli*, *Pseudomonas aeruginosa* and *Neisseria gonorrhoeae* [14][22]. A relatively minor change in porin structure can have a significant effect on functionality. For example in *Enterobacter aerogenes*, substitution of glycine with aspartate within the peptide structure of its porin, results in a narrower lumen, affecting intracellular cephalosporin transport and lowering susceptibility to antimicrobials [14].

Efflux pumps are membrane bound proteins that regulate the intracellular environment active transport mechanisms to extrude toxic compounds such as bile salts, fatty acids and heavy metals outside of bacterial cells [23]. They are important cellular machinery in increasing Gram-negative bacteria's ability to resist diverse classes of antibiotics including beta lactams, aminoglycosides and fluoroquinolones via expulsion out of the cell. These antibiotics often target intracellularly hence their expulsion restricts activity. Efflux pumps also contribute to bacterial virulence and the formation of biofilms [24]. The resistance-nodulation-division family (RND), one of five families of bacterial efflux pumps, is the only one that is specifically implicated in Gram-negative bacteria. Other families of efflux systems are extensively spread across both Gram-positive and Gram-negatives [25]. RND efflux pumps are able to expel a wide range of antibiotics with a high degree of specificity. Both RND-based efflux pumps in *Pseudomonas aeruginosa*, MexAB-OprM and MexXY-OprM, can

expel tetracycline, fluoroquinolones, and chloramphenicol, whilst for beta-lactams and novobiocin, expulsion occurs via the MexAB-OprM system [24].

Strategies for extending therapeutic activity against Gram-negatives

I. Antimicrobial peptides

Antimicrobial peptides were first isolated by Dubos in 1939 from *Bacillus* bacteria derived from soil [26]. The amphipathic nature of most antimicrobial peptides proves advantageous for antimicrobial activity. The presence of hydrophilic and hydrophobic domains allows interaction with both lipid and phospholipid groups present in the bacterial cytoplasmic membrane [27]. The majority of antimicrobial peptides are cationic in character. These naturally occurring molecules mediate an innate immune response in a multitude of organisms [28]. They possess several optimal properties for therapeutic applications. Cationic antimicrobial peptides have the ability to bind to LPS and therefore negate the production of host pro-inflammatory cytokines [29]. Most cationic antimicrobial peptides exert their bactericidal action via targeting of bacterial membranes, resulting in membrane disintegration, cell lysis and death [28]. A variety of antimicrobial peptides demonstrate an ability to permeate bacterial cell membranes at low concentrations, inhibiting DNA replication and protein synthesis without altering membrane integrity [27]. For example, buforin-II binds to DNA and RNA without disrupting the bacterial cell membrane architecture [30]. Cationic antimicrobial peptides have great potential to fill the current void in antimicrobial drug development because of their selectivity for negatively charged microbial membranes compared to neutral sterol-rich mammalian forms. Antimicrobial peptides tend to demonstrate rapid bactericidal activity utilising multiple modes of extra- and intra-cellular action. They therefore have a reduced tendency to promote bacterial resistance

189 compared to many currently licensed antimicrobials which tend to target only a single
190 biomolecular mechanism. Antimicrobial peptides are already in clinical use and such
191 examples include lysostaphin, polymyxin B and gramicidin S, demonstrating their potential
192 for clinical translation and ability to fill the void in current antimicrobial drug development
193 [31].

194
195 Polymyxins are a class of cationic cyclic lipopeptides, first discovered in 1947, isolated from
196 the spore-forming bacteria *Paenibacillus polymyxa* present in soil. Polymyxin E (colistin) and
197 polymyxin B are classified as narrow spectrum Gram-negative selective antibiotics. Their
198 clinical use decreased in the 1970s due to concerns regarding nephro- and neuro-toxicity.
199 Most recently there has been a revival in their potential clinical use and research has focused
200 on the design of novel polymyxin derivatives with markedly lower mammalian toxicity and
201 higher bactericidal activity [32]. The exact bactericidal mechanism of polymyxins has
202 remained a topic for debate amongst researchers. It has been hypothesised that the protonated
203 amino acids within the cyclic peptide structure of polymyxins, bind directly to the lipid A
204 part of LPS present in the outer membrane of Gram-negative bacteria, facilitating insertion of
205 hydrophobic motifs into the outer membrane. This enables the formation of pore-like
206 aggregates thus increasing outer membrane permeability [33]. Polymyxin B, for example, has
207 the ability to attach to the anionic surface of LPS in the outer membrane resulting in self-
208 promoted uptake into the periplasmic space and cytoplasmic membrane. It is more difficult
209 for bacteria to generate resistance against such physical interactions as it would require
210 reorganisation of vast areas of the membrane architecture. However, plasmid-borne resistance
211 has been reported recently against colistin and this is concerning as colistin is typically
212 considered a drug of last resort for Gram-negative infections [34]. The *mcr-1* plasmid,
213 identified in an *Escherichia coli* isolate present in a pig in China, encodes an enzyme that

directs the addition of phosphoethanolamine to lipid A decreasing the anionic charge of the outer membrane. Whilst this addition has been elucidated previously, the fact that the process is mediated via a plasmid is crucially significant, as it will allow resistance to readily spread to other species. This discovery highlights the urgent need for investment to elucidate antimicrobial resistance mechanisms and for tailored therapies to combat these.

Research into polymyxin-like molecules has been on-going, especially with regard to producing less toxic derivatives (nephro- and neuro-toxic) and compromising the integrity of the Gram-negative outer membrane barrier to increase the activity of existing antibiotics [35]. Structurally similar cyclic antimicrobial peptides are also of interest as future synthetic therapies as they possess increased serum stability relative to linear forms. They may also provide a basis for designing cost-effective, low molecular mass, anti-LPS compounds [36]. Cyclic peptide variants are synthesised by directly conjugating the two terminals of the primary amino acid sequence to form an amide bond, or via another form of linkage such as lactone or disulfide bonds. Generally, cyclic peptides are more effective than their linear analogues because of the structural rigidity that enables cyclic peptides to bind selectively to bacterial targets. They can also adopt an ordered amphipathic structure that allows them to insert deeper within the bacterial membrane, with extended action *in vivo* due to their increased stability to proteases [37]. Almost all known natural cyclic peptides display high antibacterial activity. For example, polymyxin B, colistimethate and gramicidin S show high bactericidal activity against *Pseudomonas aeruginosa* with minimum bactericidal concentrations of 0.125, 4 and 8 µg/ml respectively [38]. Despite their significant bacterial activity *in vitro*, many cyclic peptides are highly haemolytic and currently lack the bacterial selectivity required for clinical translation [39].

238

239 **II. Combinational antibiotic treatment for Gram-negative bacteria**

240 Synergistic therapy, a combination of two or more antibiotics, is a commonly employed
241 strategy to resolve Gram-negative infections. In comparison to monotherapy, combination
242 therapy takes advantage of the additive effects of multiple antimicrobial mechanisms for each
243 drug therapy to lower the risk of resistance developing. Combination therapy has also been
244 demonstrated to lower mortality and improve clinical outcomes. It is recommended for
245 patients whose infection is suspected or confirmed to be multidrug-resistant Gram-negative
246 bacteria [40]. Synergy between two or more antimicrobial agents means that the combined
247 effect will be greater than their individual effects. Combination therapy allows lower
248 prescribed doses of individual antimicrobials and shortens the duration of treatment reducing
249 the risk of adverse side effects to the patient [41]. Generally each individual antibiotic
250 employed varies with respect to their mode of action [42]. However, the use of multiple
251 therapies does not come without risk. Combination therapy has been associated with an
252 increase in nephrotoxicity, especially when prescribed in long term chronic infections.
253 Another disadvantage is the increased complications associated with multiple treatment
254 schedules [43]. A model combination therapy includes a broad-spectrum beta-lactam with an
255 aminoglycoside, macrolide or fluoroquinolone for treatment of *Pseudomonas* infections [40].
256 A novel combination between cephalosporins and a beta-lactamase inhibitor has been
257 recently approved [7]. A synergistic approach is a beneficial strategy that is available
258 currently to reduce the burden of antimicrobial resistance, whilst efforts intensify to identify,
259 design and test new antimicrobial therapies.

260

261 **III. The activity of silver against Gram-negative bacterial infection**

262 Silver has been known to protect against infection for over 2,000 years and continues to be
263 used widely in many antimicrobial applications, especially within the biomaterial industry.
264 Morones-Ramez and colleagues demonstrated that silver ions (Ag^+) have a synergistic effect
265 with beta-lactam, aminoglycoside and quinolone antibiotics against a variety of Gram-
266 negative bacteria. Silver has been shown to increase the production of reactive oxygen
267 species, including hydroxyl radicals ($\text{OH}\bullet$), increasing the permeability of the outer
268 membrane to commonly employed antibiotics [44]. Silver also acts intracellularly to
269 inactivate bacterial protein synthesis and enzymes responsible for a range of biochemical
270 processes, including deoxyribonuclease and ribonuclease. Silver has also been implicated in
271 DNA degradation and activation of cysteine proteases, namely the cysteine-dependent
272 aspartate-directed proteases, which play an important role in bacterial cell apoptosis. Silver
273 ion's cationic properties bestow affinity for anionic minerals present in the host, such as
274 chloride or phosphate, or proteins such as albumin. The complexes that form are inactivated
275 by precipitation or deposit in tissue debris with the potential to cause toxicity. Problems such
276 as these have led to questions regarding the safety and widespread use of silver for
277 antibacterial applications. More recently studies have focused on improving silver's ability to
278 selectively target bacterial metabolic pathways via a silver nanoparticle system [45]. Silver
279 nanoparticles have attracted interest in the development of new pharmaceutical products.
280 They have been introduced into wound dressings, medical device coatings, and are
281 increasingly utilized as drug delivery nanomaterials. Silver nanoparticle dressings, when
282 compared to silver sulfadiazine cream, have been found to decrease wound-healing time and
283 improve the clearance of bacteria from the infection site. Within medical devices, silver
284 nanoparticles have been tested as novel coatings for catheters, which are typically liable to
285 bacterial infections leading to complications such as device failure and sepsis. Furthermore,

they have the potential to be administered as drug delivery platforms, acting as carriers for licensed antibiotics and enabling penetration of the Gram-negative outer membrane [46].

Specific methods to target Gram-negative pathogens

As highlighted, the development of bacterial resistance towards existing antimicrobial agents has led to an urgent need for effective, alternative strategies. There is a necessity to develop novel classes of antibiotics and different methods to bypass current resistance mechanisms of Gram-negative bacteria [6]. There are multiple hypothesised mechanisms by which this can be achieved including: targeting membrane integrity by binding to LPS; interacting with the DsbA-DsbB enzyme system; or blocking the intracellular expulsion of antibiotics via inhibition of efflux pumps. Innovative drug delivery platforms are also considered to be “smart” approaches to enhance the efficacy of existing and future antibiotics. Genetic engineering of phage lytic enzymes is also a promising strategy with the potential to kill specific Gram-negative bacterial strains. Whilst all these approaches hold great promise, their potential for pharmaceutical scale-up and related regulatory barriers have to be considered early in the drug development process. Additionally, the high cost and the requirement to prove quality, efficacy and safety considerations are the main reason behind clinical trial failure and cessation of antimicrobial drug development [47]. Despite this, we will look further at the most promising approaches to resolving the clinical and resistance barriers that govern Gram-negative bacterial infection.

I. Negating the biological effects of Gram-negative lipopolysaccharide

As well as being the major constituent of the outer membrane, LPS signals bacterial invasion and triggers an aggressive host immune response resulting in the release of pro-inflammatory

mediators, cytokines, chemokines, and lipoproteins [48]. Lipid A is the hydrophobic portion of LPS that is chiefly responsible for biological toxicity. Within the outer membrane it protects Gram-negative bacteria from host immune defences by forming a gel-like layer of low fluidity. This layer limits the influx of hydrophobic solutes into the cell including many antibiotics [49]. Excessive host response to LPS causes organ dysfunction, septic shock and can even result in death. Antibiotics currently used to treat Gram-negative infections exacerbate the immune crisis by causing bacterial cell lysis, resulting in the release of significant amounts of LPS into the systemic circulation and creating an infection that is difficult to treat effectively [50]. The risk of these events requires consideration prior to initiation of empirical therapy as demonstrated in 2011, when the European Union witnessed a haemolytic uremic syndrome outbreak caused by Shiga toxin-producing *Escherichia coli* O104:H4. Treatment with antibiotics such as quinolones enhanced the release of its virulence factors, including LPS, resulting in multiple deaths [51].

The severity of the host response is mediated by plasma lipoproteins and the LPS-binding receptor CD14 that appears on the surface of host macrophages and neutrophils [52]. Examples of plasma lipoproteins include lipopolysaccharide-binding protein (LBP), bactericidal/permeability-increasing protein (BPI), phospholipid transfer protein and antimicrobial proteins secreted by neutrophils. Their binding to LPS causes a variety of cellular effects [53]. Both soluble LBP and CD14 are present in the blood and are known to enhance the effects of bacterial LPS. When LPS binds to LBP, the complex is recognized by host CD14 receptors that in turn activate the production of pro-inflammatory cytokines and type-I interferon, leading to local and systemic inflammatory reactions [52]. In contrast, BPI binding to LPS is thought to be inhibitory and therefore beneficial in preventing an exaggerated immune response. Recombinant and modified forms of BPI have been assessed

in clinical trials in patients with severe sepsis or septic shock. For example, recombinant BPI (rBPI₂₁) is composed of the amino-terminal half of naturally occurring BPI and possesses antibacterial and anti-LPS effects. When one amino acid cysteine residue of BPI is replaced with alanine biological stability is significantly improved without affecting the neutralizing properties of BPI [54]. This highlights how naturally occurring biomolecules can be altered synthetically to improve pharmacological and pharmaceutical properties. If harnessed correctly it will enable a wealth of potential therapies to be explored.

Throughout history nature has been the most significant source of antimicrobial therapies and there has been an increased focus on identifying novel molecules of interest from natural sources. Limulus anti-LPS factor (LALF) is an example of a small cyclic basic peptide found in haemocytes of marine chelicerates, demonstrating a strong affinity to LPS. It shows the ability to neutralize LPS by inhibiting the inflammatory cytokine tumour necrosis factor- α produced as a result of LPS stimulation of the immune response. The amino acid sequence that is responsible for LALF activity is found between amino acids 31 and 52 within the primary peptide sequence. The synthetic peptides derived from LALF 31-52 bind to LPS with high affinity and inhibits binding of LPS to LBP in a dose-dependent manner. The protective effect of LALF has been shown *in vivo* via *Escherichia coli* and *Pseudomonas aeruginosa* sepsis models in mice, with administration of LALF resulting in extended life span and decreased mortality [55].

II. Targeting disulfide bond formation by the bacterial DsbA-DsbB enzyme system of Gram-negative bacteria

The folding, stability and activity of a multitude of proteins in prokaryotic and eukaryotic cells are attributed to disulfide bonds formed between pairs of cysteines within peptide monomer units. Formation of a covalent disulfide bridge, via oxidation of sulfhydryl groups (-SH) on corresponding cysteines, is important for the stabilization of the protein tertiary structure. In bacteria disulfide bond formation is mediated by the DsbA-DsbB enzyme system. The Gram-negative bacterial genotype encodes for a diversity of cysteine-based disulfide bound proteins that are responsible for many bacterial virulence factors including toxins, adhesins, flagella, fimbriae, and secretion systems [56]. For example, *Escherichia coli* has around 300 proteins consisting of even numbers of cysteine residues that require DsbA for folding [57]. It is hypothesized therefore that inactivation of enzymes that mediate the creation of disulphide bonds in such proteins will disturb the stability and activity of related virulence factors.

In Gram-negative bacteria the periplasmic enzyme DsbA is a member of the thioredoxin family and oxidizes complementary pairs of cysteines to form disulfide bonds during their movement through the cytoplasmic membrane into the cell envelope (Figure 2) [56][58]. The resulting reduced active site cysteine of DsbA is re-oxidised by the inner membrane partner protein DsbB, restoring DsbA's activity. The subsequent reduced DsbB is reoxidized and restored using the oxidizing power of membrane-embedded quinones [59]. A number of molecules have been found that disrupt this enzymatic pathway. Landeta and colleagues discovered during screening of compounds that 4,5-dichloro-2-(2-chlorobenzyl)-3(2H)-pyridazinone inhibits disulfide bond formation in *Escherichia coli* by blockage of the DsbB enzyme *in vitro*. This compound was shown to bind covalently to the DsbB-DsbA system and inhibit *Escherichia coli* growth. 4,5-dichloro-2-(2-chlorobenzyl)-3(2H)-pyridazinone was also shown to inhibit DsbB enzymes in eight of nine tested Gram-negative pathogenic

bacteria [56]. Since the DsbA-DsbB system is responsible for disulfide bond formation in Gram-negatives, it is an essential process for the correct folding and assembly of multiple virulence factors and the bacterial cell envelope. This makes it a key target for the development of new drugs to tackle Gram-negative infection. These compounds also exhibit synergistic effects with a variety of antibiotics including beta-lactams, kanamycin, erythromycin, novobiocin, and ofloxacin [60].

III. Inactivating Gram-negative efflux pumps

RND efflux pumps in Gram-negative pathogens play an important role in bacterial resistance to a wide range of antibiotics, and so they are considered as a valuable field for development of efflux pump inhibitors (EPI) for use in combination therapy. EPIs are envisaged to increase the intracellular retention time and therefore efficacy of co-administered antibiotics [61]. As outlined previously, RND pumps in Gram-negative bacteria are responsible for exporting drugs and other toxic cations out of the cell. Their expression is upregulated in response to external stress factors, including reactive oxygen species, cell membrane injury or ribosome blocking agents [62]. The main RND efflux pumps expressed in Gram-negatives are AcrAB-TolC in *Escherichia coli* and MexAB-OprM in *Pseudomonas aeruginosa*. Located within the inner cell membrane their efflux action is mediated by bacterial periplasmic adaptor proteins and an outer membrane channel (Figure 3). If an antimicrobial agent successfully transverses the outer membrane via diffusion or porin channels, it enters the periplasmic space. Once the antibiotic is in the periplasmic space, it binds to the substrate-binding pocket of periplasmic adaptor proteins. The drug is actively transported to the outer membrane channel and into the extracellular environment. *Pseudomonas aeruginosa* PAO1 alone has 12 different RND efflux systems demonstrating the varying

complexity of bacterial efflux systems and the significant contribution they have in Gram-negative resistance [61].

The physicochemical properties of the antibiotic molecule also determines its extrusion rate by efflux pumps. RND pumps are mainly composed of an amino acid sequence with lipophilic side chains. Small hydrophilic molecules, which move rapidly through porins, possess a low efflux rate limiting their expulsion from the periplasmic space. However in *Pseudomonas aeruginosa*, porins only allow a much slower entry of small molecules and so efflux pumps can rapidly export them out of the cell. RND pumps also effectively efflux more lipophilic and larger molecules, as they diffuse slowly through the hydrophobic layer of the outer membrane. The rate of influx and active efflux of a drug can influence the minimum inhibitory concentration (MIC) of an antibiotic *in vitro* [63].

Researchers have attempted to inhibit RND efflux pumps to restore the activity of antibiotics previously deemed unusable due to the development of resistance [62]. Peptidomimetic molecules were the first synthesized EPIs. Phenylalanyl-arginyl- β -naphthylamide is a peptidomimetic compound that inhibits the levofloxacin efflux in *Pseudomonas aeruginosa* overexpressed with MexAB-OprM efflux pumps. It achieves this by directly competing with the antibiotic sites on MexAB-OprM [21]. Another novel EPI is the pyranopyridine derivative, MBX2319, which increases *Escherichia coli* sensitivity to ciprofloxacin, levofloxacin and piperacillin by inhibiting AcrAB-TolC efflux pumps. Peptidomimetic EPIs often possess cidal antibacterial activity alone but are more likely to form an important role within future clinical strategies as part of combination therapy [63].

Methods to extend the spectrum of activity of existing narrow spectrum Gram-positive antibiotics to Gram-negatives

The majority of antimicrobial agents, especially within the field of antimicrobial peptides, characterized in the laboratory setting are commonly more active against Gram-positive than Gram-negative bacteria [28]. A similar scenario exists clinically with a worrying lack of effective treatment options in reserve. Of greatest significance is the increase in resistance attributed to the Gram-negative pathogens *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae* and *Acinetobacter baumannii*, due in part to a lack of available, effective narrow spectrum Gram-negative selective antibiotics. The majority of antibiotics reserved for resistant Gram-positive infection have no activity against Gram-negatives as they are incapable of crossing the Gram-negative LPS outer membrane barrier. The critical need for urgent action in the licensing and availability of effective antimicrobials to treat Gram-negative infections clinically has led researchers to concentrate their efforts on uncovering new and effective drug delivery systems to expand and target the spectrum of activity of currently licensed antibiotics. Various platforms, including fusogenic liposomes and nanotubes are in development. They represent a novel approach to tackle the current deficit in Gram-negative antibiotics and hope to rapidly extend the currently available antibiotic library using regulatory approved Gram-positive drugs.

I. Fusogenic liposomes

Liposomes are small vesicular systems composed of an amphipathic phospholipid bilayer with an aqueous interior core. They are attractive from a drug delivery perspective due to their varying hydrophobic (membrane) and hydrophilic (core) architecture that allows the incorporation of both hydrophobic and hydrophilic drugs, including a vast range of

antibiotics. Liposomal vesicles vary widely in diameter from 0.025 to 2.5 μm [64] and demonstrate high biocompatibility and biostability resulting in prolonged circulation life [65]. Liposomes are promising molecules for antimicrobial drug delivery as the amphipathic properties of the phospholipids enable strong interactions with the bacterial membranes and enhance the release of the encapsulated drugs across them [66]. Interactions between liposomal vesicles and bacterial membranes occur via multiple mechanisms, including physical adsorption, lipid exchange and fusion. Liposomal-cell interactions are influenced by the composition of the bacterial cell membrane, the exterior structure of liposomal carrier and the biological environment [67].

Fusogenic liposomes are a variation on standard liposomal formulations consisting of inactivated Sendai virus envelope components (mainly for targeting of eukaryotic cells) or nonviral vectors involving the inclusion of specific lipids, for example amphiphilic derivatives of cholesterol including cholesterol hemisuccinate, that increase fluidity of liposomal vesicles to promote weakening of biological membranes. They demonstrate an enhanced ability to fuse with cell membranes, mixing with their lipids, resulting in delivery of vesicular contents into the cytoplasm [64]. They are promising as potential molecules to transverse the Gram-negative outer membrane, enabling delivery of antibiotics such as vancomycin to the periplasmic space. Vancomycin is a glycopeptide antibiotic with a complex chemical structure and a high molecular weight (approximately 1450 daltons). It is used clinically in the treatment of severe, multi-drug resistant Gram-positive infections. It exerts a bactericidal effect by inhibiting the synthesis of peptidoglycan, the major component of the bacterial cell wall [66]. The Gram-negative outer membrane is impermeable to vancomycin macromolecules, therefore they are intrinsically resistant. Encapsulation of vancomycin within fusogenic liposomes composed of dioleoylphosphatidylethanolamine,

dipalmitoylphosphatidylcholine and cholesterol hemisuccinate enables delivery to the periplasmic space therefore allowing activity against Gram-negative bacteria. In a study by Nicolosi and colleagues, non-encapsulated vancomycin demonstrated high MIC values, greater than 512 µg/ml for *Escherichia coli* and *Acinetobacter baumannii*, which reduced significantly to 6 µg/ml upon inclusion within this liposomal platform [68]. This demonstrates the potential of liposomal drug delivery platforms to extend the therapeutic efficacy of narrow spectrum Gram-positive therapies.

II. Carbon and peptide nanotubes

Nanotechnologies, for example nanotubes, are at the forefront of research to tackle the most difficult diseases in human and animal health. Nanotubes are materials consisting of hollow cylindrical tubes with nanoscale morphology [69]. Organic-based nanotubes are attracting increased attention as therapeutic applications, with researchers attempt to synthetically replicate the nanoscale architectures of biomolecules such as DNA. Two of the most promising nanomaterial formats are carbon and peptide-based systems [70]. Due mostly to their increased structural strength and biological stability, carbon nanotubes have attracted the attention for a range of applications throughout nanomedicine [71]. They can be formed by coiling a single layer of graphene sheet to form single-walled carbon nanotubes, or by rolling several layers to form multi-walled carbon nanotubes. The diameter of single-walled carbon nanotubes varies from 0.4 to 3.0 nm with their length ranging from 20 to 1000 nm. Their formation is driven by van der Waals intermolecular interactions increasing their structural flexibility. Multi-walled carbon nanotubes are easier to manufacture than single-walled variants, possessing an outer diameter ranging from 2 to 100 nm and inner diameter of 1 to 3 nm respectively. However, their length of 1 to several micrometres limits their structural

flexibility compared to single wall forms. Non-functionalized carbon nanotubes are insoluble in aqueous physiological media making formulation difficult and some concerns do exist regarding their safety in humans. For example, some studies have demonstrated toxicity to mammalian cells including mediators of the immune response such as macrophages due mainly to their high hydrophobic character [72].

Carbon nanotubes also lack homogeneity in terms of their size (diameters, length) this makes it difficult to effectively link the type of formulation (e.g. suspension) and concentrations to biological activity [73]. For future antimicrobial drug delivery purposes, carbon nanostructures will likely require functionalization before attachment of a drug and this can prove difficult due to the lack of chemical versatility provided by the rigid carbon-carbon covalent bond. Covalent and noncovalent surface functionalization can be performed on the synthesized carbon nanotubes facilitating the conjugation of antimicrobial agents such as the antifungal amphotericin B [69]. Specific antibacterial activity has also been demonstrated for carbon nanotubes against Gram-negative pathogens including *Escherichia coli*. Single walled nanotubes are particularly effective due to their smaller diameter and therefore increased ability to penetrate the cell wall. Carbon nanotubes display inherent antibacterial activity via physical disruption of *Escherichia coli*'s bacterial cell membrane and oxidation of bacterial glutathione resulting in oxidative stress and cell death [74]. The addition of hydroxyl (-OH) and carboxylic acid (-COOH) groups to the surface of single-walled carbon nanotubes has also been shown to enhance antimicrobial activity against Gram-positive and Gram-negative bacteria. This is due to the formation of cell-nanotube aggregates and subsequent cell wall lysis and DNA release [73]. Interestingly multi-walled carbon nanotubes do not display similar efficacy due to increased length and a reduced ability to aggregate with bacterial cells [74]. To date the majority of antibacterial carbon nanotube strategies are broad spectrum in

focus including coating with copper to eradicate *Escherichia coli* and *Staphylococcus aureus* [75]. As the Yang group confirmed, neither the difference in cell wall structures between Gram-negative and Gram-positive isolates nor the bacterial cell shape (cocci or rods), alter the effectiveness of the single-walled carbon nanotubes [73]. Carbon nanotube research has therefore been unable to selectively target Gram-negatives but the platform holds great promise in the delivery of current and future drug molecules across the outer membrane barrier.

Peptide-based nanomaterials have also received attention from researchers in the past decade due to their chemical and functional versatility. Peptide nanomaterials have many advantages over current synthetic-based materials utilised throughout healthcare. Peptides possess vast chemical flexibility attributable to variation of the amino acid R-group. As a result they can be utilised to create nanomaterials with very specific functionalities and have the potential to conjugate to a variety of molecules including antimicrobial drugs. Amino acids are the building blocks of peptides, proteins and tissues, existing throughout the body. The primary amino acid sequence of peptides can be modified in order to drive self-assembly to nanomaterials structures (nanofibers, nanotubes) in response to a range of physiochemical stimuli (pH, temperature, ionic strength, presence of specific enzymes). Self-assembling peptide platforms are gaining increasing interest as potential future antimicrobial nanotherapies. The properties required for peptide assembly to occur are similar to those that confer antimicrobial activity to the peptide, namely hydrophobic and electrostatic interactions [76].

Some of the most successful approaches to target Gram-negative bacteria have focused on utilising self-assembling linear and cyclic peptides. This is due to their ability to target bacterial cell membranes and their structural similarities to naturally occurring polymyxins [77]. Cyclic peptide nanotubes are primarily hexamers or octamers, composed of alternating amphiphilic D- and L-amino acid residues, for example L-tryptophan and D-leucine. They self-assemble into flat ring-shaped structures, with different channel diameters ranging from 0.2 to 1.3 nm [78]. Cyclic peptides can arrange into tubular open-ended structures via intermolecular interactions including hydrogen bonding. When adsorbed onto bacterial cell membranes, they have demonstrated selective membrane permeabilization and lysis of Gram-positive (*Staphylococcus aureus*) and Gram-negative (*Escherichia coli*) cells compared to mammalian cells [79]. Cyclic peptide nanotubes have great potential as synergistic antimicrobial therapies when used in conjunction with conventional antibiotics. They act as delivery systems increasing antibiotic concentration, hence antimicrobial activity, within the bacterial cell [80].

III. Targeting Gram-negative pathogens with an engineered phage lytic enzyme

Phages are viruses that demonstrate activity against bacterial cells, including multi-drug resistant Gram-negatives. They were originally studied as potential antimicrobial therapies in the United States in the 1930s and more extensively over the past 80 years in Eastern Europe [81]. Phages have been reported to be effective in resolving a variety of infections including: skin infections caused by *Pseudomonas*, *Staphylococcus*, *Proteus*, *Escherichia coli*, surgical wound infections, staphylococcal lung and pleural infections, and *Pseudomonas aeruginosa* infections in cystic fibrosis patients [82]. There are several reports that show that enzymes isolated from phages, termed lysins, may be considered as therapeutic agents. Lysins produced by bacteriophages are recombinant proteins designed to make “holes” in the cell

wall of a bacterium causing rapid cell lysis and death [83]. Until recently the action was mainly restricted to Gram-positive bacteria. Applying the same strategy to Gram-negative pathogens was considered difficult because their enzymatic target, peptidoglycan, is sequestered beneath a protective outer membrane where the lytic enzyme cannot reach. However, research by Lukacik and colleagues demonstrated that phage lytic enzymes can be engineered to cross the outer envelope of Gram-negative bacteria. This is achieved by production of hybrid lysins that have the ability to travel across the outer membrane of Gram-negatives such as *Yersinia pestis* and pathogenic *Escherichia coli* strains, breaking down the peptidoglycan layer in the periplasm. Hybrid lysin demonstrated cidal action against these strains without disrupting the outer membrane. [84]. Variations to this theme also exist. Artilyns are engineered lysins conjugated to cationic peptides extending the bactericidal activity against Gram-negatives, including *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. The inclusion of a cationic peptide disturbs the LPS outer membrane layer, allowing lysins to enter the periplasmic space resulting in degradation of peptidoglycan, cell lysis and death [83].

Conclusions

The increasing resistance of Gram-negative bacteria to a multitude of currently available antibiotics requires urgent action. Research regarding novel alternative therapies has focused on a variety of strategies, many of which have failed to progress successfully to clinical translation and utilisation for patient benefit. The majority of approaches have focused on extending the spectrum of activity of current Gram-positive targeting molecules to Gram-negatives. Whilst this warrants attention and should not be dismissed, a narrow spectrum, species targeted approach is likely to be more beneficial with greater consideration of a

601 healthy commensal microbiota. This approach requires increased ability to rapidly diagnose
602 and detect specific causative microorganisms implicated infection so that optimal targeted
603 therapy can be provided. The research strategies outlined in this review contribute to
604 expanding potential future therapeutic options at a time when clinical choices are becoming
605 increasingly limited. Currently there are clinical trials involving several antimicrobial
606 peptides. This diverse group of molecules display selective antimicrobial activity against
607 bacteria relative to mammalian cells. Whilst *in vitro* results have demonstrated promise, *in*
608 *vivo* toxicity and biostability has restricted their progress. Other successful laboratory
609 research, involving attenuation of LPS and inhibition of RND efflux, display promise in
610 limiting the severe clinical implications of Gram-negative infection. Indeed many compounds
611 that display a LPS neutralizing ability may be suitable for future clinical trials as they have
612 demonstrated both *in vitro* and animal model efficacy. RND efflux pumps inhibitors are
613 attractive compounds that improve the clinical efficacy of antibiotics in resistant bacterial
614 pathogens. Understanding biochemical pathways in Gram-negative bacterial metabolism and
615 resistance will complement the development of novel and tailored therapies. For example,
616 targeted inhibition of DsbA-DsbB enzymes prevents disulfide bond formation and the
617 formation of stable protein tertiary structures within bacterial virulence factors. Despite the
618 promise shown by such an approach no compounds have yet transferred from the laboratory
619 into clinical trials highlighting the importance of pharmaceutical formulation in advancing
620 molecular targets. Improving antibiotic delivery using liposomes or nanotubes is another
621 encouraging approach to extend therapeutic activity of conventional antibiotics against Gram-
622 negatives. There is real hope for progress within this area especially as liposomal approaches
623 have successfully resulted in licensed formulations for a variety of drugs including the
624 antifungal amphotericin B. Engineered lysins have proven to be a truly alternative approach
625 resulting in a new class of antimicrobials. However, this approach still requires further

investigation particularly with regard to patient safety and their likelihood to develop resistance.

Future Perspectives

As outlined, the need to eradicate multi-drug resistant bacteria and reduce the impending threat of resistance is an increasing challenge not only for the scientific community but society as a whole. It is everyone's responsibility to use existing antibiotics wisely in order to delay an antimicrobial crisis and allow time for the development of effective novel compounds. The research community has a key role to play in breaking down the microbial processes that lead to resistance and developing strategies to combat such biomolecular pathways. Collaboration is key for successful clinical translation. There is widespread acceptance that a targeted isolate-specific approach to eradicate multi-drug resistant bacteria is necessary to prevent treatment failure and risk of an increased number of antimicrobial resistant strains. Some of the strategies outlined in this review provide great potential for future therapeutics against Gram-negative pathogens. Key to future drug development in this area is repeating the success of the early to mid-20th century boom in antibiotic discovery. Bacteria are the most successful and innovative organisms on earth. Just as mother nature provides infectious microorganisms with the tools for survival, so too does she hold the key to solving the riddle of antimicrobial resistance. Scientists at Northeastern University Boston recently uncovered a new antibiotic molecule, teixobactin, produced by bacteria (*Eleftheria terrae*) present in soil. This molecule displays activity against *Methicillin resistant Staphylococcus aureus* and bacteria implicated in tuberculosis infections but lacks effective action against Gram-negatives. Similarly, "The Drugs from Dirt" project is a worldwide initiative aiming to harness the capability of soil bacteria and the antimicrobial compounds

they produce. Microorganisms have long been known to be capable of producing such molecules. They serve as weapons for survival facilitating destruction of competitive microbial species and enabling survival in natural environments. Therefore their ability to produce Gram-negative selective compounds seems logical. Chemically the most promising of these naturally occurring compounds are peptides. Present throughout the animal and plant kingdoms as part of the immune response, peptides are one the most effective molecules in the fight against multi-drug resistant infection. Most promising, and in contrast with many current therapies, is their ability to attack infectious microorganisms by multiple mechanisms. The ability of bacteria to develop resistance against peptides is thus significantly limited. A mining-like approach is an encouraging strategy to unlock innovative peptide antimicrobials and may eventually lead to an era of discovery and a 21st century “antimicrobial rush.” Creating patient friendly therapies, for example oral dose formulations, from the most promising of these molecules will require input from experts within the pharmaceutical industry, healthcare workers and patients themselves. Only this way will such discoveries create true value and easily translate from the laboratory to hospitals, communities and the patient.

Executive summary

Introduction

- Resistance to standard therapies employed in Gram-negative bacterial infection have increased to worrying levels over the last 30 years.
- There are a multitude of reasons for the declining clinical translation of antimicrobial drugs in the past 20 years, including safety issues highlighted in clinical trials and

concerns from the pharmaceutical industry that investment in novel therapies would not warrant a significant financial return.

The Gram-negative outer membrane as a barrier to therapy

I. Bacterial cell wall structure

- The outer membrane of Gram-negative bacteria acts as a selective barrier to the entry of a vast range of currently available antibiotic molecules.

II. Antimicrobial resistance mechanisms of Gram-negative bacterial cell wall

- Alteration of lipid A, phospholipids and/or protein composition of the outer membrane contribute to increased resistance to antimicrobial/antiseptic molecules that target the bacterial cell membrane.

Strategies for extending therapeutic activity against Gram-negatives

I. Antimicrobial peptides

- Antimicrobial peptides exist throughout nature as mediators of the innate immune response.
- Most cationic antimicrobial peptides target the bacterial cell membrane, leading to rapid cell lysis and bacterial death. They also possess multiple intracellular targets.
- Cyclic antimicrobial peptides, which are among the most promising antimicrobial agents, provide a starting point for designing low molecular mass anti-LPS compounds.

II. Combinational antibiotic treatment for Gram-negative bacteria

- Combination therapy is recommended for patients at high risk of being infected with multidrug-resistant Gram-negative bacteria, demonstrating lower mortality rates and improved clinical outcomes.

III. The activity of silver against Gram-negative bacterial infection

- Silver increases the permeability of Gram-negative bacterial membranes and can potentiate the activity of a broad range of antibiotics against these microorganisms.
- Silver nanoparticles have attracted interest due to their potential applications within wound dressings, medical device coatings, and drug delivery.

Specific methods to target Gram-negative pathogens

I. Negating the biological effects of Gram-negative lipopolysaccharide

- An important consideration when treating suspected or confirmed Gram-negative infection is preventing the biological effects of Gram-negative lipopolysaccharide. This potent molecule signals bacterial invasion and triggers defensive host responses to release pro-inflammatory mediators, cytokines, chemokines, and lipoproteins.

II. Targeting disulfide bond formation by the bacterial DsbA-DsbB enzyme system of Gram-negative bacteria

- DsbA-DsbB system in Gram-negative bacteria is a key target for the development of new drug molecules. Inhibition of disulfide bond formation has been demonstrated to prevent the assembly of key bacterial virulence factors.

III. Inactivating Gram-negative efflux pumps

- Inactivating Gram-negative efflux pumps has the potential to restore resistant antibiotics activity.

718

719 **Methods to extend the spectrum of activity of existing narrow spectrum Gram-positive**
720 **antibiotics to Gram-negatives**

721 **I. Fusogenic liposomes**

- 722 • Encapsulating narrow spectrum Gram-positive selective antibiotics within fusogenic
723 liposomes has been shown to broaden their spectrum of activity to cover Gram-negative
724 infections by enabling transversion across the outer membrane.

725 **II. Carbon and peptide nanotubes**

- 726 • Single-walled carbon nanotubes may be useful in molecules as future antimicrobials due
727 to their inherent antimicrobial properties and ability to deliver existing and future
728 antibiotic molecules via nanoparticle-based drug delivery.
- 729 • Cyclic D, L-alpha peptides are able to selectively target bacterial cell membranes,
730 including the outer membrane of Gram-negatives. They are able to self-assemble,
731 forming peptide nanotubes with the potential to act as biofunctional nanomaterials and
732 improve intracellular delivery of antibiotics.

733 **III. Targeting Gram-negative pathogens with an engineered phage lytic enzyme**

- 734 • Phage lytic enzymes can be engineered to cross the outer envelope of targeted Gram-
735 negative bacteria. This is achieved by production of a “hybrid lysin” and “artilysin” that
736 have the ability to kill pathogenic *Escherichia coli* strains and *Pseudomonas aeruginosa*.

737

738 **References**

739 1. Frieden M. Antibiotic resistance threats in the United States (2013).
740 http://www.his.org.uk/files/3713/7941/9908/Antibiotic_Resistance_Threats_in_the_United_States_2013.pdf
741

742 2. Laxminarayan R, Duse A, Wattal C *et al.* Antibiotic resistance-the need for global
743 solutions. *Lancet.Infect.Dis.* 13(12), 1057–98 (2013).

744 3. Cantóna R, Horcajadad JP, Oliver A, Garbajosaa PR, Vila J. Inappropriate use of
745 antibiotics in hospitals: the complex relationship between antibiotic use and antimicrobial
746 resistance. *Enferm.Infecc.Microbiol.Clin.* 31(Suppl 4), 3–11 (2013).

747 4. European Centre for Disease Prevention and Control (2015)
748 http://ecdc.europa.eu/en/healthtopics/Healthcare-associated_infections/Pages/index.aspx

749 5. UK 5 Year antimicrobial resistance (AMR) strategy 2013–2018 annual progress report and
750 implementation plan (2014).
751 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/385733/UK_AMR_annual_report.pdf
752

753 6. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century.
754 *Perspect.Medicin.Chem.* 6, 25–64 (2014).

755 7. Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam:
756 two novel β -lactam/ β -lactamase inhibitor combination agents for the treatment of resistant
757 Gram-negative bacterial infections. *Int.J.Antimicrob.Agents.* 46(3), 266–271 (2015).

758 8. Conly JM, and Johnston BL. Where are all the new antibiotics? The new antibiotic
759 paradox. *Can.J.Infect.Dis.Med.Microbiol.* 16(3), 159–160 (2005).

760 9. Carlet J, Jarlier V, Harbarth S *et al.* Ready for a world without antibiotics? The Pensières
761 antibiotic resistance call to action. *Antimicrob.Resist.Infect.Control.* 1(1), 11 (2012).

762 10. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. *N.*
763 *Engl. J. Med.* 362(19), 1804–1813 (2010).

764 11. Ledford H. FDA under pressure to relax drug rules. *Nature.* 492(7427), 19 (2012).

765 12. Rigel NW, Silhavy TJ. Making a beta-barrel: assembly of outer membrane proteins in
766 Gram-negative bacteria. *Curr.Opin.Microbiol.* 15(2), 189–193 (2012).

767 13. Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria:
768 biogenesis and functions. *Nat.Rev.Microbiol.* 13(10), 605–619 (2015).

769 14. Galdiero S, Falanga A, Cantisani M *et al.* Microbe-host interactions: structure and role of
770 Gram-negative bacterial porins. *Curr.Protein.Pept.Sci.* 13(8), 843–854 (2012).

771 15. Brown L, Wolf JM, Prados-Rosales R, Casadevall A. Through the wall: extracellular
772 vesicles in Gram-positive bacteria, mycobacteria and fungi. *Nat.Rev.Microbiol.* 13(10), 620–
773 630 (2015).

774 16. Blot N, Berrier C, Hugouvieux-Cotte-Pattat N, Ghazi A, Condemine G. The
775 oligogalacturonate-specific porin KdgM of *Erwinia chrysanthemi* belongs to a new porin
776 family. *J.Biol.Chem.* 277(10), 7936–7944 (2002).

777 17. Delcour AH. Outer membrane permeability and antibiotic resistance.
778 *Biochim.Biophys.Acta.* 1794(5), 808–816 (2009).

779 18. Band VI, Weiss DS. Mechanisms of antimicrobial peptide resistance in Gram-negative
780 bacteria. *Antibiotics.* 4(1), 18–41 (2015).

781 19. Pelletier MR, Casella LG, Jones JW *et al.* Unique structural modifications are present in
782 the lipopolysaccharide from colistin-resistant strains of *Acinetobacter baumannii*.
783 *Antimicrob.Agents.Chemother.* 57(10), 4831–4840 (2013).

- 784 20. Cullen TW, Giles DK, Wolf LN, Ecobichon C, Boneca IG, Trent MS. *Helicobacter*
785 *pylori* versus the host: remodeling of the bacterial outer membrane is required for survival in
786 the gastric mucosa. *PLoS.Pathog.* 7(12), e1002454 (2011).
- 787 21. Dalebroux ZD, Matamouros S, Whittington D, Bishop RE, Miller SI. PhoPQ regulates
788 acidic glycerophospholipid content of the *Salmonella Typhimurium* outer membrane.
789 *Proc.Natl.Acad.Sci.* 111(5), 1963–1968 (2014).
- 790 22. Pagès JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective
791 diffusion barrier in Gram-negative bacteria. *Nat.Rev.Microbiol.* 6(12), 893–903 (2008).
- 792 23. Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-
793 negative bacteria: molecular mechanism and inhibition. *Front.Microbiol.* 6, 377 (2015).
- 794 24. Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and
795 pharmacological exploitations. *Biochem.Biophys.Res.Commun.* 453(2), 254–267 (2014).
- 796 25. Alvarez-Ortega C, Olivares J, Martínez JL. RND multidrug efflux pumps: what are they
797 good for? *Front.Microbiol.* 4, 7 (2013).
- 798 26. Dubos RJ. Studies on a bacterial agent extracted from a soil *Bacillus*: I. preparation of the
799 agent. Its activity *in vitro*. *J.Exp.Med.* 70(1), 1–10 (1939).
- 800 27. Bahar AA, Ren D. Antimicrobial peptides. *Pharmaceuticals.* 6(12), 1543–1575 (2013).
- 801 28. Laverty G, Gorman SP, Gilmore BF. The potential of antimicrobial peptides as biocides.
802 *Int.J.Mol.Sci.* 12(10), 6566–6596 (2011).
- 803 29. Giuliani A, Pirri G, Rinaldi AC. Antimicrobial peptides: the LPS connection.
804 *Methods.Mol.Biol.* 618, 137–154 (2010).

805 30. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin-II:
806 buforin-II kills microorganisms by penetrating the cell membrane and inhibiting cellular
807 functions. *Biochem.Biophys.Res.Comm.* 244(1), 253–257 (1998).

808 31. Bradshaw J. Cationic antimicrobial peptides: issues for potential clinical use. *Bio.Drugs*.
809 17(4), 233-240 (2003).

810 32. Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial mechanisms of polymyxin and bacterial
811 resistance. *BioMed.Res.Int*, 679109 (2015).

812 33. Velkov T, Roberts KD, Nation RL, *et al*. Pharmacology of polymyxins: new insights into
813 an ‘old’ class of antibiotics. *Future.Microbiol.* 8(6), 10.2217/fmb.13.39 (2013).

814 34. Liu YY, Wang Y, Walsh TR, *et al*. Emergence of plasmid-mediated colistin resistance
815 mechanism *MCR-1* in animals and human beings in China: a microbiological and molecular
816 biological study. *Lancet.Infect.Dis.* 16(2), 161–168 (2016).

817 35. Vaara M. Polymyxins and their novel derivative. *Curr.Opin.Microbiol.* 13(5), 574-81
818 (2010).

819 36. Park SC, Park Y, Hahm HS. The role of antimicrobial peptides in preventing multidrug-
820 resistant bacterial infections and biofilm formation. *Int.J.Mol.Sci.* 12(9), 5971–5992 (2011).

821 37. Joo SH. Cyclic peptides as therapeutic agents and biochemical tools. *Biomol.Ther.* 20(1),
822 19–26 (2012).

823 38. Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. Interactions of bacterial cationic
824 peptide antibiotics with outer and cytoplasmic membranes of *Pseudomonas aeruginosa*.
825 *Antimicrob.Agents.Chemother.* 44(12), 3317–21 (2000).

826 39. Kondejewski LH, Jelokhani-Niaraki M, Farmer SW *et al.* Dissociation of antimicrobial
827 and hemolytic activities in cyclic peptide diastereomers by systematic alterations in
828 amphipathicity. *J.Biol.Chem.* 274(19), 13181–13192 (1999).

829 40. Tängdén T. Combination antibiotic therapy for multi-drug resistant Gram-negative
830 bacteria, *Ups.J.Med.Sci.* 119(2), 149–153 (2014).

831 41. Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing "side effects" of
832 pharmaceuticals on society and the environment. *Sci.Total.Environ.* 443, 324–337 (2013).

833 42. Kim S, Lieberman TD, Kishony R. Alternating antibiotic treatments constrain
834 evolutionary paths to multidrug resistance. *Proc.Natl.Acad.Sci.* 111(40), 14494–9 (2014).

835 43. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of
836 infections with Gram-negative bacteria. *Clin.Microbiol.Rev.* 25(3), 450–470 (2012).

837 44. Morones-Ramirez RJ, Winkler JA, Spina CS, Collins JJ. Silver enhances antibiotic
838 activity against Gram-negative bacteria. *Sci.Transl.Med.* 5(190), 190ra81 (2013).

839 45. Lee W, Kim KJ, Lee DG. A novel mechanism for the antibacterial effect of silver
840 nanoparticles on *Escherichia coli*. *Biometals.* 6, 1191–1201 (2014).

841 46. Ge L, Li Q, Wang M, Ouyang J, Li X, Xing MM. Nanosilver particles in medical
842 applications: synthesis, performance, and toxicity. *Int.J.Nanomedicine.* 9, 2399–407 (2014).

843 47. Gupta SK, Nayak RP. Dry antibiotic pipeline: regulatory bottlenecks and regulatory
844 reforms. *J.Pharmacol.Pharmacother.* 5(1), 4–7 (2014).

845 48. Berthet J, Damiana P, Hamzeh-Cognasse H *et al.* Human platelets can discriminate
846 between various bacterial LPS isoforms via TLR4 signaling and differential cytokine
847 secretion. *Clin.Immunol.* 145(3), 189–200 (2012).

848 49. Nikado H. Molecular basis of bacterial outer membrane permeability revisited. *Microbiol*
849 *Mol.Biol. Rev.* 67(4), 593–656 (2003).

850 50. Harvey M, Cave G. Co-administration of phospholipid emulsion with first dose
851 bactericidal antibiotic may retard progression of the sepsis response in Gram-negative
852 septicaemia. *Med.Hypotheses.* 83(5), 563–565 (2014).

853 51. Kunsmann L, Rüter C, Bauwens A *et al.* Virulence from vesicles: novel mechanisms of
854 host cell injury by *Escherichia coli* O104:H4 outbreak strain. *Sci.Rep.* 5, 13252 (2015).

855 52. Płóciennikowska A, Hromada-Judycka A, Borzęcka K, Kwiatkowska K. Co-operation of
856 TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. *Cell.Mol.Life.Sci.* 72(3),
857 557–581 (2015).

858 53. Schumann RR. Old and new findings on lipopolysaccharide-binding protein: a soluble
859 pattern-recognition molecule. *Biochem.Soc.Trans.* 39(4), 989–993 (2011).

860 54. Domingues MM, Lopes SC, Santos NC, Quintas A, Castanho MA. Fold-unfold
861 transitions in the selectivity and mechanism of action of the N-terminal fragment of the
862 bactericidal/permeability-increasing protein (rBPI₂₁). *Biophys.J.* 96(3), 987–96 (2009).

863 55. Liu Y, Ni B, Ren JD *et al.* Cyclic limulus anti-lipopolysaccharide (LPS) factor-derived
864 peptide CLP-19 antagonizes LPS function by blocking binding to LPS binding protein.
865 *Biol.Pharm.Bull.* 34(11), 1678–1683 (2011).

866 56. Landeta C, Blazyk JL, Hatahet F. Compounds targeting disulfide bond forming enzyme
867 DsbB of Gram-negative bacteria. *Nat.Chem.Biol.* 11(4), 292–298 (2015).

868 57. Dutton RJ, Boyd D, Berkmen M, Beckwith J. Bacterial species exhibit diversity in their
869 mechanisms and capacity for protein disulfide bond formation. *Proc.Natl.Acad.Sci.* 105,
870 11933–11938 (2008).

871 58. Depuydt M, Messens J, Collet JF. How proteins form disulfide bonds.
872 *Antioxid.Redox.Signal.* 15(1), 49–66 (2011).

873 59. Inaba K, Murakami S, Suzuki M *et al.* Crystal structure of the DsbB-DsbA complex
874 reveals a mechanism of disulfide bond generation. *Cell.* 127(4), 789–801 (2006).

875 60. Hayashi S , Abe M, Kimoto M, Furukawa S, Nakazawa T. The DsbA-DsbB disulfide
876 bond formation system of *Burkholderia cepacia* is involved in the production of protease and
877 alkaline phosphatase, motility, metal resistance, and multi-drug resistance.
878 *Microbiol.Immunol.* 44(1), 41–50 (2000).

879 61. Opperman TJ, Kwasny SM, Kim HS *et al.* Characterization of a novel pyranopyridine
880 inhibitor of the AcrAB efflux pump of *Escherichia coli*. *Antimicrob.Agents.Chemother.*
881 58(2), 722–733 (2014).

882 62. Dreier J, Ruggerone P. Interaction of antibacterial compounds with RND efflux pumps in
883 *Pseudomonas aeruginosa*. *Front.Microbiol.* 6, 660 (2015).

884 63. Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in
885 Gram-negative bacteria. *Clin.Microbiol.Rev.* 28(2), 337–418 (2015).

886 64. Akbarzadeh A, Rezaei-Sadabady R, Davaran S *et al.* Liposome: classification,
887 preparation, and applications. *Nanoscale.Res.Lett.* 8(1), 102 (2013).

888 65. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical
889 applications. *Adv.Drug.Deliv.Rev.* 65(1), 36–48 (2013).

890 66. Colzi I, Troyan AN, Perito B *et al.* Antibiotic delivery by liposomes from prokaryotic
891 microorganisms: *Similia cum similibus* works better. *Eur J Pharm Biopharm.* 94, 411–418
892 (2015).

893 67. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers.
894 *Nature.Rev.Drug.Discovery*. 4(2), 145–160 (2005).

895 68. Nicolosi D, Scalia M, Nicolosi VM, Pignatello R. Encapsulation in fusogenic liposomes
896 broadens the spectrum of action of vancomycin against Gram-negative bacteria.
897 *Int.J.Antimicrob.Agents*. 35(6), 553–5589 (2010).

898 69. Elhissi AM, Ahmed W, Hassan IU, Dhanak VR, D'Emanuele A. Carbon nanotubes in
899 cancer therapy and drug delivery. *J.Drug.Deliv*. 837327 (2012).

900 70. Zhu X, Radovic-Moreno AF, Wu J, Langer R, Shi J. Nanomedicine in the management of
901 microbial infection - overview and perspectives. *Nano.Today*. 9(4), 478–498 (2014).

902 71. Usui Y, Haniu H, Tsuruoka S, Saito N. Carbon nanotubes innovate on medical
903 technology. *Med.Chem*. 2(1), 1–6 (2012).

904 72. Rastogi V, Yadav P, Bhattacharya SS *et al*. Carbon nanotubes: an emerging drug carrier
905 for targeting cancer cells. *J.Drug.Deliv*. 670815 (2014).

906 73. Arias LR, Yang L. Inactivation of bacterial pathogens by carbon nanotubes in
907 suspensions. *Langmuir*. 25(5), 3003-3012 (2009).

908 74. Yang C, Mamouni J, Tang Y, Yang L. Antimicrobial activity of single-walled carbon
909 nanotubes: length effect. *Langmuir*. 26(20), 16013-16019 (2010).

910 75. Liu T, Tang H, Zhao J, Li D, Li R, Sun X. A study on the bactericidal properties of Cu-
911 coated carbon nanotubes. *Front.Mater.Sci*. 1(2), 147–150 (2007).

912 76. McCloskey AP, Gilmore BF, Lavery G. Evolution of antimicrobial peptides to self-
913 assembled peptides for biomaterial applications. *Pathogens*. 3(4), 791-821 (2014).

914

- 915 77. Zhang L, Dhillon P, Yan H, Farmer S, Hancock R.E. Interactions of bacterial cationic
916 peptide antibiotics with outer and cytoplasmic membranes of *Pseudomonas aeruginosa*.
917 *Antimicrob.Agents.Chemother.* 44, 3317-3321 (2000).
- 918 78. Chapman R, Danial M, Koh ML, Jolliffe KA, Perrier S. Design and properties of
919 functional nanotubes from the self-assembly of cyclic peptide templates. *Chem.Soc.Rev.*
920 41(18), 6023–41 (2012).
- 921 79. Fernandez-Lopez S, Kim HS, Choi EC *et al.* Antibacterial agents based on the cyclic
922 D,L-alpha-peptide architecture. *Nature.* 412(6845), 452–5 (2001).
- 923 80. Rodríguez-Vázquez N, Ozores HL, Guerra A *et al.* Membrane-targeted self-assembling
924 cyclic peptide nanotubes. *Curr.Top.Med.Chem.* 14(23), 2647–61 (2014).
- 925 81. Trudil D. Phage lytic enzymes: a history. *Viol.Sin.* 30(1), 26–32 (2015)
- 926 82. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections.
927 *Bacteriophage.* 1(2), 66–85 (2011).
- 928 83. Briers Y, Walmagh M, Van Puyenbroeck *et al.* Engineered endolysin-based "Artilysins"
929 to combat multidrug-resistant Gram-negative pathogens. *MBio.* 5(4), e01379–14 (2014).
- 930 84. Lukacik P, Barnard TJ, Hinnebusch BJ, Buchanan SK. Specific targeting and killing of
931 Gram-negative pathogens with an engineered phage lytic enzyme. *Virulence.* 4(1), 90–96
932 (2013).

933

934 **Reference annotations**

935 * [9] Carlet J, Jarlier V, Harbarth S, *et al.* Ready for a world without antibiotics? The
936 Pensières antibiotic resistance call to action. *Antimicrob. Resist. Infect. Control.* 1(1), 11
937 (2012).

938 Reveals the dramatic rise of Gram-negative resistance to antibiotics and the importance in
939 a global solution to the crisis.

940 ** [14] Galdiero S, Falanga A, Cantisani M, *et al.* Microbe-host interactions: structure
941 and role of Gram-negative bacterial porins. *Curr. Protein. Pept. Sci.* 13(8), 843–854 (2012).

942 Reviews the role of porins in activating immunological responses and their influence
943 within antibiotic resistance mechanisms.

944 ** [17] Delcour AH. Outer membrane permeability and antibiotic resistance.
945 *Biochim. Biophys. Acta.* 1794(5), 808–816 (2009).

946 This review outlines possible mechanisms for permeating the Gram-negative outer
947 membrane and the bacterial pathways that modify its architecture to resist antibiotics.

948 ** [18] Band VI, Weiss DS. Mechanisms of antimicrobial peptide resistance in Gram-
949 negative bacteria. *Antibiotics.* 4(1), 18–41 (2015).

950 Provides an overview of the biomolecular mechanisms utilized by Gram-negative bacteria
951 to increase resistance to antimicrobial peptides.

952 ** [23] Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from
953 Gram-negative bacteria: molecular mechanism and inhibition. *Front. Microbiol.* 6, 377
954 (2015).

955 Explores RND efflux pumps and the development of new compounds to limit their
956 impact.

957 * [84] Lukacik P, Barnard TJ, Hinnebusch BJ, Buchanan SK. *Virulence*. 4(1), 90–96
958 (2013).

959 Provides a proof of principle that phage lytic enzymes such as T4 lysozyme can be
960 engineered to target Gram-negative bacteria.

961

962 **Financial disclosure/Acknowledgements**

963 None of the authors has any financial or personal relationships that could inappropriately
964 influence or bias the content of the paper. GL acknowledges funding provided by the Queen's
965 University Research Support Package for New Academic Staff and a Royal Society Research
966 Grant (RG150171).

967